retatrutide parkinson's clinical trial First phase 3 data for are here folks. This drug is a barn burner. This was only 68 weeks and was geared towards osteoarthritis of the knee. Massive pain improvements and Eli Lilly infiltrates anti-obesity market

Ambery P, Parker VE, Sumvoll M et al (2018) MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomized, controlled, double-blind, ascending dose and phase 2A study

In the prescription medication industry, there are single glucagon-like peptide-1 (GLP-1) receptor agonist options (weight loss injections) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist options that are marketed for the treatment of diabetes, obesity, and weight management solutions

He points to intragastric balloons, or IGBs

Why GLP-1s May Not Be the Answer for Most Women Over 40 These drugs don't address the root causes of weight gain in midlife women: Hormonal shifts (like declining estrogen) Increased stress and cortisol Changes in sleep, energy, and metabolism Gut microbiome imbalances (which in fact, we know these injections can worsen) Most people regain weight after stopping injections unless they've made sustainable changes alongside the medication

The inpatient admission copay will be $425 per day